Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial.

Juan Pablo FriasJaeDuk ChoiJulio RosenstockLuiza PopescuElisabeth NiemoellerIsabel Muehlen-BartmerSeungJae Baek

Published in: Diabetes care (2022)

As monotherapy in patients with type 2 diabetes, once-weekly efpeglenatide significantly improved glycemic control and body weight with a safety and tolerability profile similar to that of other GLP-1 RAs.

Keyphrases

glycemic control
body weight
type diabetes
open label
randomized controlled trial
study protocol
combination therapy
phase iii
blood glucose
double blind
weight loss
insulin resistance
clinical trial
placebo controlled
cardiovascular disease
resting state
wild type
systematic review